CMG Pharmaceutical Co., Ltd.

As of March 31, 2026, CMG Pharmaceutical Co., Ltd. carries a market capitalization of 257.54B, placing it among publicly traded companies globally. Its enterprise value stands at 319.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, CMG Pharmaceutical Co., Ltd. has 147.84M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 2.30, and the price-to-book ratio stands at 1.28.

These figures are as of March 31, 2026. The EV/Sales ratio of 2.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 319.26B versus a market cap of 257.54B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, CMG Pharmaceutical Co., Ltd. maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.77, indicating elevated leverage, while an interest coverage ratio of -1.17 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, CMG Pharmaceutical Co., Ltd. posted a negative return on equity (ROE) of -4.30, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.68, reflecting losses generated across the asset base. The company generates approximately 451.31M in revenue per employee across its workforce of 244.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.65 indicates how many times CMG Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, CMG Pharmaceutical Co., Ltd. recorded an income tax benefit of -1.76B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -10.15B and -8.38B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 30, 2026, CMG Pharmaceutical Co., Ltd.'s stock has declined approximately 69.36% over the past 52 weeks. The 50-day moving average sits at 642.24, while the 200-day moving average is 1,383.08.

Over the twelve months ended March 31, 2026, CMG Pharmaceutical Co., Ltd. generated 110.12B in revenue and converted that into -8.38B in net income, yielding earnings per share of -57.60. EBITDA reached -2.38B, while operating income came in at -5.28B.

As of March 31, 2026, CMG Pharmaceutical Co., Ltd. holds 26.58B in cash and equivalents against 88.30B in total debt, resulting in a net debt position of 78.87B. Total book value stands at 201.72B, with working capital of 18.57B providing operational flexibility.

CMG Pharmaceutical Co., Ltd. produced -10.38B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -43.31B in capital expenditures, free cash flow totaled -53.69B - equivalent to -368.93 per share.

Over the twelve months ended March 31, 2026, CMG Pharmaceutical Co., Ltd. posted a gross margin of 56.88, reflecting its pricing power and cost economics. The operating margin of -4.80 and net profit margin of -7.61 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -21.18: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.27, meaning CMG Pharmaceutical Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

CMG Pharmaceutical Co., Ltd.'s most recent stock split took place on June 13, 2019 with a 381:409 split ratio.

As of March 31, 2026, CMG Pharmaceutical Co., Ltd. has an Altman Z-Score of 1.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.